The latest (2020) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection Version 2.2020 August 24, 2020 recommends annual PSA screening for men with known BRCA1/2 pathogenic variants due to their increased risk of subclinical, high-grade disease, increased mortality and earlier age at diagnosis [79]. The gene discussed is BRCA1; the disease is prostate cancer.